Clinical Trials Logo

Blood Group Antigen Abnormality clinical trials

View clinical trials related to Blood Group Antigen Abnormality.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05859958 Completed - COVID-19 Clinical Trials

ABO Blood Group Type Association With COVID-19 Severity

Start date: November 10, 2022
Phase:
Study type: Observational

The COVID-19 pandemic has caused a significant healthcare burden and remains a heavily researched disease entity. Originating in Wuhan, China in late 2019, SARS-CoV-2 has infected over 600 million individuals worldwide. ABO blood groups have been known to increase the human body's susceptibility to different pathogens, such as hepatitis B virus, MERS-COV, SARS-COV, norovirus, and malaria, to name a few. As such, the association of ABO blood groups and COVID-19 infection and disease severity has come into question.

NCT ID: NCT03727230 Completed - Blood Transfusion Clinical Trials

RhD+ Blood Transfusion to Asian-type DEL Recipients

Start date: October 1, 2016
Phase: N/A
Study type: Interventional

Red blood cells (RBCs) from Asian-type DEL blood group express very weak RhD antigen and are falsely typed as RhD-negative blood group in routine RhD testing. Until now, Asian-type DEL (D-eluate) patients still be treated as rare RhD-negative patients in the clinic. Previous study from the Asian-type DEL pregnant women with RhD+ fetus showed no occurrence of alloanti-D immunization. This result, however, does not directly be applied for Asian-type DEL patients receiving RhD+ blood transfusions, as lacking of direct evidence regarding the safety and underlying mechanism. In this study, the patients with Asian-type DEL were identified and received RhD+ blood transfusion, then evaluations of any adverse reactions, especially the active follow-up alloantibody test, were prospectively conducted.